MYC and cholangiocarcinoma: However, the IC50 of the MYC inhibitor against CCA cell viability was higher than the reported plasma concentration (58.2 μM) at 24 h and 48 h, ranging between 117.3 μM and 50.17 μM, respectively, for the KKU-M213 cell line, and 260.3 μM and 65.75 μM for the RBE cell line (Figure 6, Supplementary Table S6).